| Bioactivity | SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity[1]. |
| Target | SLC7A11 |
| Invitro | SLC7A11-IN-1 (compound 2; 0-100 µM; 72 h) 显示出抗增殖活性，对于 HCT-116, MDA-MB-231, MCF-7, HepG2, LO2 细胞的 IC50 值分别为 0.03、0.11、0.18、0.17、0.27 µM[1]。SLC7A11-IN-1 (0.5 µM; 24 h) 抑制 HCT-116 细胞的侵袭和转移[1]。SLC7A11-IN-1 (0.5 µM; 24 h) 诱导细胞凋亡和细胞周期停滞在 S 期[1]。SLC7A11-IN-1明显降低细胞内 GSH 含量，显着增强活性氧 (ROS) 的表达[1]。SLC7A11-IN-1 (1 µM; 15 h) 显著诱导 HCT-116 细胞的 DNA 损伤和相关蛋白表达[1]。 Cell Cycle Analysis[1] Cell Line: |
| In Vivo | SLC7A11-IN-1 (2 mg/kg; i.v.; 每三天连续3次) 抑制小鼠肿瘤的生长[1] Animal Model: |
| Name | SLC7A11-IN-1 |
| Formula | C13H15Cl2F3N4O5PtS |
| Molar Mass | 662.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li Z, et al. Blocking xCT and PI3K/Akt pathway synergized with DNA damage of Riluzole-Pt(IV) prodrugs for cancer treatment. Eur J Med Chem. 2023 Mar 15;250:115233. |